Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD
Canadian Association of Radiologists Journal · 2026
DOI: 10.1177/08465371251357447 ↗Kurz gefasst
Leitlinie in der Zeitschrift Canadian Association of Radiologists Journal, 2026. Verfasst von Mitchell P Wilson und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway using serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) programs. In Part 2 of these guidelines, the WG provides 14 recommendations for risk stratifying MASLD patients into low and high risk for advanced hepatic fibrosis ( F ≥ 3) using a combination of serological and imaging investigations. Population screening and risk stratification of MASLD patients using a clinical and serological investigation (FIB-4) followed by imaging pathway is recommended. Clinical, technical, and grading recommendations for point shear wave elastography (pSWE), 2-dimensional SWE (2D-SWE), and MRE are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Alberta, Edmonton, AB, Canada.
- University of Calgary, Calgary, AB, Canada.
- Dalhousie University, Halifax, NS, Canada.
- Université de Montréal, Montréal, QC, Canada.
- University of British Columbia, Vancouver, BC, Canada.
- McGill University, Montreal, QC, Canada.
ORCID-Profile: Mitchell P Wilson, Gavin Low, Andreu F Costa, An Tang, Silvia Chang, Alexandra Medellin, Jérémy Dana, Ania Kielar, Li Xin Zhang, Daisy Fung, Casey Hurrell, Christopher Fung
Zitieren
APA
Wilson, M. P., Low, G., Shaheen, A. A., Costa, A. F., Tang, A., Pang, E., Chang, S., Medellin, A., Dana, J., Millo, N., Kielar, A., Zhang, L. X., Whitaker, T., Swain, M., Leung, V., Fung, D., Hurrell, C., & Fung, C. (2026). Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD. Canadian Association of Radiologists Journal. https://doi.org/10.1177/08465371251357447
Vancouver
Wilson MP, Low G, Shaheen AA, Costa AF, Tang A, Pang E, et al. Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD. Canadian Association of Radiologists Journal. 2026. doi:10.1177/08465371251357447
BibTeX
@article{Wilson2026,
author = {Wilson, Mitchell P and Low, Gavin and Shaheen, Abdel-Aziz and Costa, Andreu F and Tang, An and Pang, Emily and Chang, Silvia and Medellin, Alexandra and Dana, Jérémy and Millo, Noam and Kielar, Ania and Zhang, Li Xin and Whitaker, Toni and Swain, Mark and Leung, Victoria and Fung, Daisy and Hurrell, Casey and Fung, Christopher},
title = {Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD},
journal = {Canadian Association of Radiologists Journal},
year = {2026},
doi = {10.1177/08465371251357447}
}
EUVIMED